<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033120</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00102384</org_study_id>
    <nct_id>NCT04033120</nct_id>
  </id_info>
  <brief_title>Making an Early Diagnosis of Talaromycosis Using a Novel Antigen Test</brief_title>
  <official_title>Making an Early Diagnosis of Talaromycosis - a Strategy to Reduce Morbidity and Mortality in Advanced HIV Disease in Southeast Asia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oxford University Clinical Research Unit, Vietnam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Hospital for Tropical Diseases, Hanoi, Vietnam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to determine whether a new antigen detection test called Mp1p EIA&#xD;
      can make an early diagnosis of talaromycosis from the blood and urine of patients.&#xD;
      Talaromycosis is a life-threatening infection caused by a fungus endemic in Southeast Asia&#xD;
      commonly found in patients with advanced HIV disease called Talaromyces marneffei.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to determine the diagnostic and prognostic values and the clinical impact of&#xD;
      Talaromyces marneffei antigenemia (TmAg) in patients with advanced HIV disease using a novel&#xD;
      enzyme immunoassay (EIA) detecting Tm-specific cell wall mannoprotein Mp1p. The data&#xD;
      generated will be used to inform the design of future diagnostic clinical trials to test the&#xD;
      utility of screening and providing pre-emptive antifungal therapy to prevent disease and&#xD;
      reduce HIV mortality in Southeast Asia.&#xD;
&#xD;
      The primary objective is to screen for TmAg and determine its diagnostic and prognostic&#xD;
      performance in symptomatic and asymptomatic HIV-infected patients with a CD4 count ≤100&#xD;
      cells/mm3.&#xD;
&#xD;
      We will test the following hypotheses:&#xD;
&#xD;
        1. In symptomatic hospitalized patient Cohort 1, the sensitivity of the Mp1p EIA will be&#xD;
           higher than conventional culture method while simultaneously specificity is higher than&#xD;
           95% for diagnosing culture-confirmed talaromycosis over a six-month follow up period&#xD;
&#xD;
        2. In asymptomatic outpatient Cohort 2, there will be at least 30% difference in risk of&#xD;
           talaromycosis development in TmAg-positive patients compared to TmAg-negative patients&#xD;
           over a twelve-month follow up period&#xD;
&#xD;
        3. TmAg concentration predicts development of talaromycosis&#xD;
&#xD;
      Secondary Objectives include:&#xD;
&#xD;
        1. To assess the impact of presence of TmAg on clinical outcomes, including development of&#xD;
           culture-confirmed talaromycosis, incidence of state III and IV AIDS events, subsequent&#xD;
           hospitalizations, and death over six- to twelve-month follow up periods&#xD;
&#xD;
        2. To compare the diagnostic values of the Mp1p EIA when performed in plasma, sera, and&#xD;
           urine samples and when performed in these matrices in combination&#xD;
&#xD;
           We will test the following hypotheses:&#xD;
&#xD;
        3. To model the health economic benefits of screening and pre-emptive treatment for&#xD;
           pre-clinical infection&#xD;
&#xD;
        4. To assess impact on clinic outcomes of screening all patients for cryptococcosis and&#xD;
           histoplasmosis&#xD;
&#xD;
        5. To collect additional blood samples and store left-over samples for future research to&#xD;
           validate infectious disease diagnostics and research to understand genetic&#xD;
           susceptibility to infectious diseases relevant to HIV population&#xD;
&#xD;
      Participants in the study, will be asked questions about their medical and travel history.&#xD;
      Participants will have blood and urine collected for the Mp1p EIA test to look for early&#xD;
      talaromycosis infection and for other tests to look for common HIV-associated infections&#xD;
      including tuberculosis, cryptococcosis, and histoplasmosis. They will be examined by a study&#xD;
      doctor at least once weekly if they are in the hospital and will be followed in clinic&#xD;
      monthly for between 6 and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of microscopy and/or culture-confirmed talaromycosis</measure>
    <time_frame>over six to twelve months</time_frame>
    <description>Cumulative incidence of microscopic and or culture-confirmed talaromycosis over six to twelve months will be recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of other major HIV-associated opportunistic infections</measure>
    <time_frame>over six to twelve months</time_frame>
    <description>Opportunistic infections to be recorded include: tuberculosis, cryptococcosis, and histoplasmosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stage III and IV AIDS events</measure>
    <time_frame>over six to twelve months</time_frame>
    <description>Cumulative incidence of HIV stage III and IV event according to WHO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations in the subsequent six to twelve months</measure>
    <time_frame>over six to twelve months</time_frame>
    <description>Cumulative incidence of hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in the subsequent six months (Cohort 1) and twelve months (Cohort 2)</measure>
    <time_frame>over six to twelve months</time_frame>
    <description>All cause mortality will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of loss to follow up</measure>
    <time_frame>over six to twelve months</time_frame>
    <description>Loss of follow up is defined as missing &gt;3 consecutive clinic visits</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>AIDS/HIV - RelatedDisease Associated With AIDS</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Cohort 1: Symptomatic hospitalized patients: 900 patients admitted to the participating hospitals whom doctors suspect to have an infection and will perform TmAg testing alongside routine diagnostics and the following additional diagnostics:&#xD;
MycoF/lytic blood culture system&#xD;
Fujifilm lateral flow urine lipoarabinomannan (LF-LAM) test for tuberculosis&#xD;
Cryptotoccoal antigen in sera (CrAg) LFA for cryptococcosis&#xD;
Histoplasma antigen in urine (HAg) LFA for histoplasmosis&#xD;
We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a six-month follow up period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Cohort 2: Asymptomatic outpatients: 500 patients registered at the outpatient clinics at the participating hospitals whom doctors do not suspect of having an active infection and will perform TmAg testing alongside the following diagnostics:&#xD;
CrAg LFA for cryptococcosis&#xD;
HAg LFA for histoplasmosis&#xD;
We will follow patients closely for early diagnosis and treatment of culture confirmed talaromycosis over a twelve-month follow up period.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients age ≥18 years with advanced HIV disease who have a CD4 count ≤100&#xD;
        cells/mm3 within the past 3 months, who are admitted to hospitals with a suspected&#xD;
        infection (Cohort 1) or who are asymptomatic and registered in HIV outpatient clinic&#xD;
        (Cohort 2) in Vietnam&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HIV-1 infection (at least 2 of 3 HIV antibody tests are positive), AND&#xD;
&#xD;
          2. HIV-infected age ≥18 years, AND&#xD;
&#xD;
          3. CD4 count ≤100 cells/mm3 within the past 3 months, AND&#xD;
&#xD;
          4. Antiretroviral therapy (ART) naïve OR recent ART ≤3 months OR suspected or confirmed&#xD;
             treatment failure on ART ≥12 months (defined as poor treatment adherence, treatment&#xD;
             interruption, or having a confirmed HIV RNA ≥1,000 copies)&#xD;
&#xD;
          5. Cohort 1: suspected to have an active infection&#xD;
&#xD;
          6. Cohort 2: not suspected to have or being evaluated for an active infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unlikely to attend regular clinic visits&#xD;
&#xD;
          2. History of recent talaromycosis or histoplasmosis infection currently on antifungal&#xD;
             therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thuy Le, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thuy Le, MD, PhD</last_name>
    <phone>919-668-5053</phone>
    <email>thuy.le@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rogier van Doorn, MD, PhD</last_name>
    <phone>+84 4 3576 4320</phone>
    <email>rvandoorn@oucru.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital for Tropical Diseases</name>
      <address>
        <city>Ho Chi Minh City</city>
        <state>Ward 1 District 5</state>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nguyen Van Vinh Chau, MD, PhD</last_name>
      <phone>84.8.923.5804</phone>
      <email>chaunvv@oucru.org</email>
    </contact>
    <contact_backup>
      <last_name>Vo Trieu Ly, MD</last_name>
      <phone>84.8.923.5804</phone>
      <email>drtrieuly@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Hospital for Tropical Diseases</name>
      <address>
        <city>Hà Nội</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nguyen Van Kinh, MD PhD</last_name>
      <phone>84.4.3576.4320</phone>
      <email>kinhnv@nhtd.vn</email>
    </contact>
    <contact_backup>
      <last_name>Vu Quoc Dat, MD</last_name>
      <phone>84.4.3576.4320</phone>
      <email>datvq@oucru.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>talaromycosis</keyword>
  <keyword>endemic mycoses</keyword>
  <keyword>opportunistic infections</keyword>
  <keyword>penicilliosis</keyword>
  <keyword>Southeast Asia</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

